The temporal profile of calcineurin inhibition by cyclosporine in vivo
- PMID: 10573076
- DOI: 10.1097/00007890-199911150-00023
The temporal profile of calcineurin inhibition by cyclosporine in vivo
Abstract
Background: Cyclosporine (CsA) acts by inhibiting the phosphatase calcineurin (CN), but the time course and extent of inhibition in vivo are unknown. We examined the effect of single oral CsA doses on CN activity in humans and mice in vivo.
Methods: In humans, blood CsA levels were determined and CN activity was measured in whole blood and in blood leukocytes of patients up to 12 hr after CsA dosing (just before the second dose). Samples were collected from patients receiving a first single dose (2.5 mg/kg), and up to 14 days later after repeated dosing. In mice, after CsA dosing (12.5-200 mg/kg) by oral gavage, CsA levels in blood and tissue (spleen, kidney) were determined and CN activity was measured in spleen and kidney.
Results: In humans, peak CsA levels of 800-2285 microg/L at 1-2 hr produced 70-96% CN inhibition. Inhibition correlated closely with the rise and fall of CsA levels with no observable lag at the times sampled. Repeated doses showed similar CN inhibition to first dose, with no significant adaptation. In mice, CsA peaked at 1 hr in blood, spleen, and kidney, with higher concentrations in spleen and kidney than in blood. CN inhibition closely followed CsA concentrations/doses, and was greater in kidney than spleen.
Conclusion: Thus CsA induces partial CN inhibition that varies directly with the blood and tissue levels, and may be greater in some tissues due to higher drug accumulation. The high CsA concentrations and CN inhibition in kidney may be relevant to nephrotoxicity.
Similar articles
-
Quantitating immunosuppression. Estimating the 50% inhibitory concentration for in vivo cyclosporine in mice.Transplantation. 1996 Jun 15;61(11):1618-24. doi: 10.1097/00007890-199606150-00012. Transplantation. 1996. PMID: 8669107
-
Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations.Transplantation. 2000 Jul 27;70(2):327-35. doi: 10.1097/00007890-200007270-00017. Transplantation. 2000. PMID: 10933159
-
Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients.Clin Chem. 2001 Sep;47(9):1679-87. Clin Chem. 2001. PMID: 11514403
-
Variation in leukocyte subset concentrations affects calcineurin activity measurement: implications for pharmacodynamic monitoring strategies.Clin Chem. 2008 Mar;54(3):517-24. doi: 10.1373/clinchem.2007.097253. Epub 2008 Jan 24. Clin Chem. 2008. PMID: 18218723
-
ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications.Transplant Proc. 2001 May;33(3):2420-1. doi: 10.1016/s0041-1345(01)02059-0. Transplant Proc. 2001. PMID: 11377580 Review. No abstract available.
Cited by
-
Cyclosporin therapeutic drug monitoring--an established service revisited.Clin Biochem Rev. 2003 May;24(2):33-46. Clin Biochem Rev. 2003. PMID: 18568053 Free PMC article.
-
Therapeutic drug monitoring in pediatric renal transplantation.Pediatr Nephrol. 2015 Feb;30(2):253-65. doi: 10.1007/s00467-014-2813-8. Epub 2014 Apr 25. Pediatr Nephrol. 2015. PMID: 24763544 Review.
-
Effects of oral cyclosporine on canine T-cell expression of IL-2 and IFN-gamma across a 12-h dosing interval.J Vet Pharmacol Ther. 2016 Jun;39(3):237-44. doi: 10.1111/jvp.12280. Epub 2015 Dec 17. J Vet Pharmacol Ther. 2016. PMID: 26676223 Free PMC article. Clinical Trial.
-
Expression of calcineurin activity after lung transplantation: a 2-year follow-up.PLoS One. 2013;8(3):e59634. doi: 10.1371/journal.pone.0059634. Epub 2013 Mar 25. PLoS One. 2013. PMID: 23536885 Free PMC article.
-
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.Cancer Cell. 2010 Jul 13;18(1):74-87. doi: 10.1016/j.ccr.2010.04.025. Cancer Cell. 2010. PMID: 20609354 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources